Short Interest in Celularity Inc. (NASDAQ:CELU) Increases By 7.1%

Celularity Inc. (NASDAQ:CELUGet Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 395,600 shares, an increase of 7.1% from the December 31st total of 369,300 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is currently 0.4 days. Approximately 4.2% of the shares of the company are short sold.

Celularity Stock Down 0.2 %

Shares of CELU traded down $0.01 during mid-day trading on Tuesday, hitting $2.02. The company’s stock had a trading volume of 19,401 shares, compared to its average volume of 71,290. Celularity has a one year low of $1.30 and a one year high of $7.97. The stock’s 50-day moving average is $2.23 and its two-hundred day moving average is $2.56.

Celularity (NASDAQ:CELUGet Free Report) last released its earnings results on Friday, December 6th. The company reported ($0.73) earnings per share for the quarter. Celularity had a negative net margin of 72.72% and a negative return on equity of 119.53%.

About Celularity

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

Featured Articles

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.